Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 673, “The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma,” presented by Craig H. Moskowitz, MD.
Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 232, “Long-Term Complications After Splenectomy in Adult Chronic Immune Thrombocytopenia With a Minimum Follow-up of 10 Years: First Results From a Single-Center Case-Control Study in 140 Patients With Primary ITP,” presented by Lan-huong Thai.
Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 504, “Final Analysis of the RO-CHOP Phase Ib/II Study: Romidepsin in Association With CHOP in Patients With Peripheral T-Cell Lymphoma (PTCL)” presented by Jehan Dupuis, MD.
Time: 1:53
Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “Rituximab Maintenance vs Wait and Watch After Four Courses of R-DHAP Followed By Autologous Stem Cell Transplantation in Previously Untreated Young Patients With Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a Lysa Study,” presented by Steven Le Gouill, MD, PhD.
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53, “ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults With Beta-Thalassemia: Preliminary Results From a Phase II Study,” presented by Antonio G. Piga, MD.
Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 4848, “Implementation of a Heparin-Induced Thrombocytopenia Management Program Reduces the Cost of Diagnostic Testing and Pharmacologic Treatment in an Academic Medical Center,” presented by Caroline Dupre Vaughn, RN.
